Indication

Ocular histoplasmosis

Ocular histoplasmosis, commonly referred to as presumed ocular histoplasmosis syndrome (POHS), is a multifocal chorioretinal disorder thought to arise as a late manifestation following hematogenous dissemination of the fungus *Histoplasma capsulatum*. Read more about Ocular histoplasmosis

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Ocular histoplasmosis therapies.

Showing 1–3 of 3 drugs

VISUDYNE (verteporfin)

OPHTHALMIC - PHOTODYNAMIC THERAPY AGENTS·CHOROIDAL NEOVASCULARIZATION·+3
Bausch Health US

VISUDYNE (verteporfin)

OPHTHALMIC - PHOTODYNAMIC THERAPY AGENTS·CHOROIDAL NEOVASCULARIZATION·+3
BAUSCH & LOMB P
Filter & compare in the drug finder →Opens the drug finder with Ocular histoplasmosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Ocular histoplasmosis.

Ocular histoplasmosis, commonly referred to as presumed ocular histoplasmosis syndrome (POHS), is a multifocal chorioretinal disorder thought to arise as a late manifestation following hematogenous dissemination of the fungus *Histoplasma capsulatum*.

It primarily affects adults aged 20 to 50 who reside in or have visited endemic areas, such as the Ohio and Mississippi River valleys.

The condition is clinically defined by a classic triad of punched-out peripheral or midperipheral chorioretinal scars ("histo spots"), peripapillary atrophy, and maculopathy secondary to choroidal neovascularization, notably occurring in the complete absence of vitritis or anterior segment inflammation.

While the early peripheral scars are typically asymptomatic, vision impairment develops when subretinal neovascular complexes bleed, leak fluid, or induce disciform macular scarring.

Personalize your experience

Follow Ocular histoplasmosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it